

# Point of Care Diagnostic Device for Early Detection of Osteoarthritis

*BME 5151 Spring 2022*

Carolyn, Davis, Tim, and Lindsey



# Osteoarthritis

## Definition

Irreversible degradation of protective cartilage in the joints

## Symptoms

Pain, swelling, stiffness, tenderness loss of flexibility, grating sensation

## Risk Factors

Older age, sex, obesity, joint injuries, genetics, deformaties, repeated stress



# Current Treatments

## Medications

- Acetaminophen
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Cymbalta

## Therapy

- Physical Therapy
- Occupational Therapy
- Transcutaneous Electrical Nerve Stimulation (TENS)

## Procedures

- Cortisone Injections
- Lubrication Injections
- Realigning Bones
- Joint Replacement

# Limitations of Current Technology

## 1 No devices for early detection

Earlier treatment can reduce pain and discomfort.

## 2 Cartilage loss revealed by X-rays

Loss of space between bones revealed by imaging.

## 3 Joint fluid analysis to test for inflammation

Fluid extracted from affected joint to determine if cause is infection or OA.



# Design Proposal

*Combining biomarker counting and a sensor to confirm biomarker type for the most accurate and earliest detection of OA via synovial fluid*



# Targeted OA Biomarkers

## Cytokines


- Proteins secreted by immune cells
- Bind to synovial macrophages
- Leads to degradation of collagen that maintains joint structure

## hYKL-39 Antibody

- Binds with YKL-39 antigen
- Synthesises chondrocytes & synovial cells in inflammation or remodels the cell matrix
- Important for cartilage remodelling & degradation in OA joints

# Biological Targets for Device Design

## Osteoarthritis related-cytokines



### IL-1 $\beta$ , TNF- $\alpha$


Suppresses type II collagen and aggrecan expression  
Stimulates the release of MMP-1, MMP-3 and MMP-13  
Induces the production of IL-6 and chemokines

### IL-6

Upregulates MMP-1 and MMP-13


### IL-17

Induces IL-1 $\beta$ , TNF- $\alpha$ , IL-6  
Upregulates NO and MMPs  
Downregulates proteoglycan






# Digital Microfluidics to Manipulate Discrete Droplets



DMF Platform  
on Riser




Driver PCB with High  
Voltage Power Supply





# Digital Microfluidics to Manipulate Discrete Droplets




# Principles of Device Operation

Electrowetting  
Dielectric Principle

Time Constant  
Capacitive Measurement

Receptor Placed on  
top of  $\text{SiO}_2$





# Device Material Selection

**AlN Ceramic PCB:** Excellent thermal conductivity, high insulation resistance, mass production

**ALD of  $\text{HfO}_2$ :** Excellent dielectric constant to reduce operation voltage.

**Cy Top:** Hydrophobic coating

**$\text{SiO}_2$ :** Surface to grow aptamer



# Device Stackup

Standard Device Cutaway

HfO<sub>2</sub>

Au

Cu

AlN

Cu

CyTop Hydrophobic Coating

HfO<sub>2</sub>

Au

Cu

AlN

Cu

Au

Cu

AlN

Cu

SiO<sub>2</sub>

Au

Cu

AlN

Cu



# Device Fabrication


ITO Glass

CyTop  
Hydrophobic  
Coating

Electrode

AlN

Cu Interconnect



Electrode




Capacitive  
Sensor

Our method of employing capacitive measurement is to apply a DC voltage into the electrode and measure the  $T=RC$  constant where  $T$  is the time where the voltage at the electrode is  $\frac{1}{2} VDD$ .

Cu, Au, SiO<sub>2</sub>



# Signal Acquisition





# Testing and Validation

Quantitative characterization of capacitive versus concentration curves.

Unbinding method between proteins and antibody for reusability.



Hysteresis characterization of binding events

Overall precision and accuracy





# Expected Result




# Limitations & Challenges

Early Detection  $\neq$  Cure



Invasive to get appropriate sample



Concentration of biomarker may not be enough to signal OA





# Future Directions

- Potential for drug modeling purposes?
- Improving quality of analytical biomarkers
- Could be generalized to other joints to expand diagnostic capabilities
- As with most new technology, increasing accessibility by decreasing cost and size





# Conclusions

- Osteoarthritis is a degenerative disease that occurs when the flexible tissue at the end of the bones wears down
- Our device aims to be able to more accurately and efficiently diagnose the disease using bioMEMS technology
- There are certainly limiting factors, but it has exciting prospects for the future of early diagnosis





**Thank you!**

Questions?

# References

Camacho-Encina, María et al. "Discovery of an autoantibody signature for the early diagnosis of knee osteoarthritis: data from the Osteoarthritis Initiative." *Annals of the rheumatic diseases* vol. 78,12 (2019): 1699-1705.

Centers for Disease Control and Prevention. (2020, July 27). *Osteoarthritis (OA)*. Centers for Disease Control and Prevention. Retrieved April 26, 2022.

Haseeb, Abdul, and Tariq M Haqqi. "Immunopathogenesis of osteoarthritis." *Clinical immunology (Orlando, Fla.)* vol. 146,3 (2013): 185-96.

Chaocharoen, Wethaka & Ranok, Araya & Suginta, Wipa & Schulte, Albert. (2015). A microfluidic capacitive immunosensor system for human cartilage chitinase-3-like protein 2 (hYKL-39) quantification as osteoarthritis marker in synovial joint fluid. *RSC Adv.* 5

Kim KH, Jo JH, Cho HJ, Park TS, Kim TM. Therapeutic potential of stem cell-derived extracellular vesicles in osteoarthritis: preclinical study findings. *Lab Anim Res.* 2020 Apr 15;36:10.

Mayo Foundation for Medical Education and Research. (2021, June 16). *Osteoarthritis - Symptoms and Causes*. Mayo Clinic. Retrieved April 26, 2022.

Kim, Jinmyeong et al. "Recent Advances in Aptasensor for Cytokine Detection: A Review." *Sensors (Basel, Switzerland)* vol. 21,24 8491. 20 Dec. 2021, doi:10.3390/s21248491